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Central hypovolemia, defined as diminished blood volume in the heart and pulmonary 
vascular bed, is still an unresolved problem from a therapeutic point of view. The devel-
opment of pharmaceutical agents targeted at specific angiotensin II receptors, such as 
the non-peptidergic AT2-receptor agonist compound 21, is yielding many opportunities 
to uncover more knowledge about angiotensin II receptor profiles and possible thera-
peutic use. Cardiovascular, anti-inflammatory, and neuroprotective therapeutic use of 
compound 21 have been suggested. However, there has not yet been a focus on the 
use of these agents in a hypovolemic setting. We argue that the latest debates on the 
effect of angiotensin II during hypovolemia might guide for future studies, investigating 
the effect of such agents during experimentally simulated central hypovolemia. The 
purpose of this review is to examine the role of angiotensin II during episodes of central 
hypovolemia. To examine this, we reviewed results from studies with three experimental 
models of simulated hypovolemia: head up tilt table test, lower body negative pressure, 
and hemorrhage of animals. A systemic literature search was made with the use of 
PubMed/MEDLINE for studies that measured variables of the renin–angiotensin system 
or its effect during simulated hypovolemia. Twelve articles, using one of the three models, 
were included and showed a possible organ-protective effect and an effect on the sym-
pathetic system of angiotensin II during hypovolemia. The results support the possible 
organ-protective vasodilatory role for the AT2-receptor during hypovolemia on both the 
kidney and the splanchnic tissue.
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inTRODUCTiOn
Central hypovolemia, defined as diminished blood volume in the heart and pulmonary vasculary 
bed (1), is a potentially life-threatening condition that left untreated leads to hemorrhagic shock 
(2). However, the therapeutic strategy for central hypovolemia is debated and still unresolved (3, 4). 
Expanding our knowledge about the hormones that act to stabilize the hemodynamic conditions 
during hypovolemia is essential to proposing new therapeutic strategies.
During World War II, an increase in the interest in hypovolemic shock gave rise to a large body of 
research on the hemodynamic effects of central hypovolemia (5–8). This research shed light on many 
of the now well-known hemodynamic effects of central hypovolemia and developed the broadly 
used experimental models for simulating central hypovolemia. There are three experimental models 
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generally accepted as valid: head up tilt table, hemorrhage, and 
lower body negative pressure (1, 9). Head up tilt is an experimen-
tal model in which subjects, in the supine position, are raised to 
a head up position of various degrees, thereby allowing the larger 
part of the blood volume to move toward the lower extremities 
inducing an experimentally simulated central hypovolemia (1, 
10). Lower body negative pressure consists of a design that induces 
negative pressure surrounding the lower extremities thereby 
driving the blood from the thoracic circulation to the lower 
extremities. The third experimental model is the hemorrhage in 
animals to a point of registered central hypovolemia. Trials using 
these experimental models investigated the endocrine effects of 
central hypovolemia, uncovering the now well-established rise 
in epinephrine, aldosterone, and angiotensin II during the late 
phase of central hypovolemia (1).
Angiotensin II, the end product of the renin–angiotensin 
system (RAS), is a hormone involved in maintaining blood 
pressure. Under normal circumstances, this system works by 
increasing fluid intake through dipsogenic effect mediated by 
the subfornical organ and by retaining sodium and water by the 
adrenal release of aldosterone along with a direct effect on the 
proximal tubule (11–14).
Angiontensin II increases the activity of the sodium–hydro-
gen antiporter in the proximal tubule and causes a vasocon-
striction of the efferent and afferent arteriole leading to a shift 
of the Starling forces. Both of these effects favor water and 
sodium reabsorption (12, 13, 15). During central hypervolemia, 
angiotensin II acts as a vasopressor by inducing peripheral vaso-
constriction (14, 15). Angiotensin II acts through four-subtype 
receptors label AT1–4.
In the early 90s, a growing number of pharmaceutical 
agents regulating the synthesis or blocking specific receptors of 
angiotensin II where developed. By the use of these agents during 
experimentally simulated central hypovolemia, it was possible 
to isolate different aspects of angiotensin II’s effects and locate 
them to specific subtype receptors. The use of an antagonist of 
the angiotensin II receptor subtype 1 (AT1-receptor) during 
simulated central hypovolemia resulted in a drop in mean arterial 
pressure, total peripheral resistance, and systemic vascular resist-
ance. This lead to the conclusion that the G-coupled AT1-receptor 
localized in cardiac, vascular, pulmonary, renal, and adrenal 
tissue AT1-receptor is the main mediator of the vasoconstrictor 
effect of angiotensin II during hypovolemia (15–25). The role 
of the G-coupled AT2-receptor during hypovolemia is still not 
certain (15). Still no apparent studies have been carried out using 
a selective AT2-receptor agonist in experimentally simulated 
central hypovolemia. The non-peptidergic AT2-receptor agonist 
compound 21 is yielding many opportunities to uncover more 
knowledge about angiotensin II receptor profiles and possible 
therapeutic use.
Angiotensin II can be cleaved to Angiotensin (1–7) by the 
normally sparse enzyme Angiotensin Conversing Enzyme 2 (26). 
Angiotensin (1–7) is postulated to counteract the pressor effect of 
Angiotensin II and via the G-coupled Ang(1–7) receptor (26–28).
A number of studies have reported that losartan, the most 
common AT1-receptor antagonist, accentuated the hypotensive 
response to orthostatic stress compared with other AT1-receptor 
antagonists and angiotensin-converting enzyme (ACE) inhibi-
tors (18, 24, 25). Such an effect may indicate that losartan in itself 
have an effect beyond AT1-receptor antagonism. These results 
have since given rise to several different hypotheses and explana-
tions to why losartan and other AT1-receptor antagonists have an 
accentuated orthostatic hypotensive effect compared with other 
general angiotensin receptor antagonists and ACE-inhibitors 
(18, 22, 24, 25, 29). The studies of the effect of losartan have 
revived older debates on the interaction of angiotensin II with 
the sympathetic system. It is undisputed that angiotensin II has 
a blunting effect on the baroreflex, but whether this is mediated 
either centrally or peripherally is still disputed (30–34).
The purpose of this review is to examine the role of angiotensin 
II during episodes of central hypovolemia.
MeTHODS
The search was executed using the search terms: “((((((head up 
tilt) OR hypovolemia) OR Lower body negative pressure AND 
angiotensin) NOT thirst) NOT hypertension Filters: Clinical 
Trial, Comparative Study, Controlled Clinical Trial, Randomized 
Controlled Trial, Case Reports, English Abstract, Evaluation 
Studies, In Vitro, Observational Study, Twin Study))” in pubmed/
MEDLINE. The latest search was performed in October 2015. 
This approach provided a result of 445 articles. After applying the 
following inclusion criteria: studies using AT1-receptor antago-
nist; both human and animal experiments; articles in English, 
Spanish, or Scandinavian (Danish, Swedish, or Norwegian), 
72 remained. Exclusion criteria were the following: diagnosis 
expected of essentially altering RAS during experimentally 
simulated central hypovolemia (e.g., hypertension); articles that 
did not include a model of experimentally simulated central 
hypovolemia. The latter also applied with a set of cut-offs, as 
defined at the end of this section. The search gave eight eligible 
articles. Further four articles were included by reference lists. 
This gave a total of 12 eligible articles. Of the eligible articles, five 
were head up tilt table, five studies were hemorrhage of animals, 
and two were lower body negative pressure, as shown in Figure 1. 
There was a relatively even distribution between the three differ-
ent designs. There was a predominance of studies with animal 
subjects but there was no noteworthy difference in the number 
of subjects (see Table 1).
CUT-OFFS AnD COMPARiSOnS OF 
MODeLS
The following cut-offs are made to insure that the response to the 
hypovolemia models stimuli elicited a hormonal response rather 
than a purely baroreceptor-mediated compensation. The mini-
mum amount of degrees raised in head up tilt table is 30, since 
that seems to be the lowest tilt where non-baroreceptor response 
has been observed (1, 32). The amount of negative pressure in 
lower body negative pressure models needed to sufficiently 
simulate central hypovolemia is disputed (38). A moderately con-
servative cut-off is that above −40 mmHg the organism does not 
treat the design as central hypovolemia (39–42). Others  suggest 
FiGURe 1 | Flowchart of study selection.
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−50 mmHg (43). This article will use the −40 mmHg cut-off as 
accepted induced pressure.
Below 20% hemorrhage of total blood volume in some species, 
the carotid sinus maintains mean arterial pressure and central 
hypovolemia will not be observed (44, 45). The temporal dimen-
sion was also considered in all three models. Although there was 
no clear temporal cut-off, no studies were included that did not 
have reasonable temporal dimensions.
Two recent studies have compared the three models and have 
found similar results regarding conversion of degrees in head 
up tilt table, mmHg negative pressure, and percentage of total 
blood volume (40, 43). The cut-off values chosen for each of the 
three models of simulated central hypovolemia is similar when 
converted with the conversions of these two studies.
Head up tilt table tends to produce a larger fluctuation in 
mean arterial pressure, which might originate from an activation 
of vestibular control on the cardiovascular system, whereas lower 
body negative pressure increases heart rate relatively more. There 
tend to be a higher vascular resistance change in the lower, com-
pared to the upper, body in head up tilt, compared to lower body 
negative pressure, which produce an equal change in lower and 
upper body (46).
ReSULTS
Explaining the accentuated orthostatic response of losartan has 
lead to two general areas of interest for analysis of angiotensin 
II’s effect during episodes of experimentally simulated central 
hypovolemia. One argued that, when the AT1-receptor is blocked, 
the rise in angiotensin II implies that there will be a correspond-
ing increase in the stimulation of other angiotensin II receptors. 
Most relevant in this context is the AT2-receptor and Ang(1–7) 
(15, 20–22). The other argues that losartan seems to be blunting 
a sympathetic effect of angiotensin II (18, 22, 24, 25).
TABLe 1 | List of eligible studies.
Author Result Model N Subject Use of antagonist 
or inhibitor
Aneman et al. (35) During hypovolemia, AT1RA animals had improved portal venous 
blood flow and jejunal mucosal perfusion maintenance and better 
survival rate
Hemorrhage 20 Pigs – landrace AT1RA
Bedette et al. (22) Lorsartan have the same AT1RA. AT1RA’s kan cross the  
blood–brain barrier and can have its effect on pre-motor neurons 
Head up tilt table 10–14 Rats AT1RA
de Moura et al. (18) The marked orthostatic cardiovascular response of losartan may 
be due, in part, to an interaction of this antagonist with Ang-(1–7) 
receptors




Franke et al. (36) During the LBNP, GFR decreased significantly during 
cardiopulmonary stress testing in the subjects taking the placebo 
and remained unchanged in those under treatment with AT1RA
Lower body negative 
pressure
18 Human AT1RA
Hashimoto et al. (24) During hypovolemia losartan result in prolonged orthostatic 
hypotensive effect compared to other AT1RA
Head up tilt table Rats AT1RA
Hatton et al. (19) Angiotensin II have an effect on the sympathetic system mediated 
by the AT1-recpetor. The site of action I peripherally
Lower body negative 
pressure
– Cats AT1RA and 
ACE-inhibitor
Johansson et al. (23) Hypovolemia was seen to inhibit alkaline secretion and that 
angiotensin II potentiated that inhibition. Furthermore, it is argued 
in favor of a peripheral site of action of angiotensin II on the 
sympathetic nervous system




Laesser et al. (37) Jeujenal perfusion is accentuated by AT1RA and activation of 
intestinal AT2-receptors may play a significant role in improving the 
outcome of severe hypovolemia
Hemorrhage 53 Pigs – Landrace AT1RA and AT2RA
Ohlstein et al. (25) Losartan have an effect beyond AT1-receptor antagonism. With 
accentuated orthostatic intolerance
Head up tilt table 22 Rats AT1RA and 
ACE-inhibitors
Pancera et al. (16) Losartan has inhibitory effect on the sympathetic activity and 
maintained vagal activity
Head up tilt table 18 Human AT1RA
Ryckwaert et al. (21) Selective AT1-receptor blockade was associated with a 
vasodilatation and a preservation of CO and SV. It is speculated 
that the dilation is due to overstimulation of the AT2-receptor





The results suggest that AT2-receptor had only small if any 
contribution to a systemic vasodilatation observed during  
AT1-receptor blockade
Hemorrhage 18 Piglets – farm 
bred
AT1RA and AT2RA
AT1RA, AT1-receptor antagonist and AT2RA, AT2-receptor antagonist.
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ORGAn-SPeCiFiC PROTeCTive 
FUnCTiOn OF AT2-ReCePTOR
Initially, the hypothesis was that the overstimulation of the 
 AT2-receptor resulted in a systemic vasodilation (21, 47). Ryckwaert 
et al. found that, when an AT1-receptor antagonist was used dur-
ing 20 and 40% total blood volume hemorrhage in pigs (N = 18), 
there was a significant fall in vascular resistance compared with 
ACE-inhibitors (21). Further selective AT1-receptor blockade was 
associated with a vasodilatation. This lead to the initial hypothesis, 
which seemed likely since several studies have observed that the AT2-
receptor has a vasodilatory effect in some tissues (15, 38, 48–50). 
However, other studies observed that the vasodilatory effect of the 
AT2-receptor was not dominant during hypovolemia (51). Ryckwaert 
et al. tested the hypothesis in a later study using both AT1-receptor 
antagonists, AT1-receptor alone, and together with AT2-receptor 
antagonists during experimentally simulated central hypovolemia. 
The result did not show a significant systemic difference between the 
two groups leading to the conclusion that there is no systemic effect 
of overstimulation of the AT2-receptor during hypovolemia (20).
Even though there is no evidence of a systemic role of the 
 AT2-receptor during central hypovolemia, there is some evidence 
supporting an organ-specific vasodilatory role for the AT2-
receptor. Examining the kidney function during experimentally 
simulated central hypovolemia, it is observed that AT1-receptor 
antagonists help maintain the GFR despite a reduction in RPF 
and RBF compared with controls (29). This suggests a role of 
the angiotensin II that is not mediated by the AT1-receptor. The 
relatively high expression of the AT2-receptor in the kidney, 
intestines, and other tissues, together with findings that the AT2-
receptor antagonist increases pressure and decreases nitric oxide 
concentration is in favor of an organ-specific role (15, 47, 52).
In a study in which landrace pigs (N = 53) underwent a 30% 
total blood volume hemorrhage, it was reported that survival rates 
were higher in the group, which were only given AT1-receptor 
antagonist, compared with the group given both AT1-receptor 
and AT2-receptor antagonists (37). The authors found that 
during AT1-receptor antagonism only, and hence comparative 
overstimulation of the AT2-receptor, the jejunal intraluminal 
nitric oxide output was significantly higher. During hypovolemia, 
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there was a greater expression of the AT2-receptor in the jejunum. 
This indicates that AT2-receptor would have an organ-protective 
function during hypovolemia in the small intestines. A study 
using an AT1-receptor antagonist in pigs during a 40% total 
blood volume hemorrhage found increased jejunal perfusion and 
portal venous flow compared with a control group and increased 
survival among AT1-receptor antagonist-treated pigs (35).
POSSiBLe ROLe FOR THe AnG(1–7) 
ReCePTOR
de Moura et  al. have suggested a possible role for Ang(1–7) 
receptors in episodes of central hypovolemia, arguing that 
the augmenting effect of losartan is due to a stimulation of the 
Ang(1–7)-receptor. They presented evidence that the combined 
use of losartan with a Ang(1–7)-receptor antagonist leads to a 
removing of the bradycardic effect of losartan resulting in a 
blunting of the orthostatic response of losartan (18). Analogously 
Ryckwaert el al. (20) have suggested that the fall in vascular resist-
ance observed with a AT1-receptor antagonist might originate 
from increased metabolites, such as Ang(1–7) or Ang(4), which 
might have vasodilatory properties (53–55).
SYMPATHeTiC ACTiOnS OF 
AnGiOTenSin ii DURinG 
eXPeRiMenTALLY SiMULATeD CenTRAL 
HYPOvOLeMiA
The debate about sympathetic stimulation of angiotensin II is 
centered on the question whether angiotensin II has a central 
or a peripheral site of action on the sympathetic system during 
central hypovolemia.
That angiotensin II can have a potentiating effect on the 
sympathetic system is well-known (25, 56, 57). Hatton et al. was 
the first to suggest that angiotensin II has a sympathetic effect 
during hypovolemia. They observed a prolonged negative effect 
on arterial pressure during lower body negative pressure with 
ACE-inhibitors compared with an AT1-receptor antagonist. They 
further observed that there was not a reduced efferent nerve 
activity and, hence, suggested a peripheral site of action for 
angiotensin II (19).
Ohlstein et  al.’s result from head up tilt table test gave the 
first evidence for a specific AT1-receptor-mediated sympathetic 
effect during hypovolemia. The accentuated hypotensive effect 
of losartan led them to suggest that the stimulation of specific 
receptors at the site of the primary baroreceptor synapse (25). 
Johansson et  al. found that a moderate hemorrhage of 10% of 
the total blood volume induced a significant fall of nearly 50% 
in mucosal alkaline secretion in rats (N = 18). This effect could 
be reversed by the administration of an AT1-receptor antagonist 
and elevated by administration of exogenous angiotensin II. 
This suggested that angiotensin II had a prolonging effect on 
symphato-adrenergic inhibition of mucosal alkaline secretion 
acting specifically on efferent secremotor neuron in the intestines 
(23). Angiotensin II was administered to ACE-inhibitor-treated 
animals and a significant inhibitory effect was observed during 
direct splanchnic nerve stimulation (23). This indicates the pres-
ence of a peripheral mechanism of action (23).
Pancera et al.’s head up tilt table tests in human subjects showed 
that losartan inhibits the sympathetic activity and maintained 
vagal activity. This suggests a direct sympathetic function of the 
AT1-receptor and a vagally inhibitory function of angiotensin II 
acting peripherally (16).
Using head tilt table, Bedette et  al. showed that conscious 
rats treated with losartan seem to have the same compensatory 
mechanism as with other AT1-receptor antagonists. Bedette et al. 
argued that AT1-receptor antagonists can cross the blood–brain 
barrier and that the reason for an accentuated orthostatic effect 
of losartan is due to a differentially centrally mediated action of 
the AT1-receptor antagonists (22, 58).
DiSCUSSiOn
The evidence suggests an organ-protective function of angioten-
sin II in splanchnic tissue, most prominently the kidney and the 
intestines. The results of investigating angiotensin II’s interaction 
with the sympathetic system during experimentally simulated 
central hypovolemia are indicating both centrally and a peripher-
ally mediated inhibition of the baroreflex (16, 23).
There is evidence supporting the organ-protective role of the 
AT2-receptor in studies that are not using one of the three models 
of hypovolemia (47). As splanchnic ischemia and acute renal 
failure are recognizable factors in postoperative morbidity (59), 
a possible protective function yield a number of possible uses for 
AT2-receptor agonists (60). One promising candidate for an AT2 
agonist is the non-peptide “Compound 21” developed by Vicore 
Pharma AB (61).
Although seemingly not addressed so far, future pharmaceuti-
cal use, using one of the models for central hypovolemia might 
be relevant if further evidence support an organ-protective role 
during hypovolemia (35) and potentially opening the use of this 
and other AT2 agonist in hypovolemic therapy.
Ang(1–7) could represent an explanation for some of the 
vasodilatory actions seen with AT1-receptor antagonists. There 
are arguments for such an effect, including losartan-sensitive 
Ang(1–7) receptors, in the heart (62) and kidney (55, 63). However, 
the results contraindicate this finding (64) and de Moura et al.’s 
conclusion is seemingly that the effect is at best minor (18).
Studies have shown both peripheral and central mechanism of 
Angiotensin II in studies with one of the models of hypovolemia.
Bedette et al.’s argue that the effect of AT1 antagonist is obscured 
by the anesthetic blunting of the sympathetic system. They pre-
sent the suggestive hypothesis that AT1 antagonists depending on 
pharmacological specificity might give differential interference 
with central pre-motor neurons. This cannot be ruled out since 
the AT1 antagonist is able to pass the blood–brain barrier and 
could lead to the altered response. However, the anesthetic effect 
cannot explain the physiological evidence for both centrally 
(65–69) and some peripheral site of action (34, 70) in studies not 
using one of the three models.
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COnCLUSiOn
There is evidence supporting an organ-protective function of the 
AT2. A study with one of the three accepted models of simulated 
hypovolemia could be used to verify this, with an AT2 agonist 
such as compound 21 (61). The verification of an  organ-protective 
function could yield the use of such agents in hypovolemic 
therapy.
Further studies aimed at distinguishing between a  AT2-receptor 
stimulation and a Ang(1–7) stimulation could prove useful to 
clarify the presence of a synergistic effect.
There is evidence supporting that the blunting of the barore-
flex by angiotensin II is a combination of peripheral and central 
mechanism and that it is mediated by the AT1-receptor. Future 
trials investigating angiotensin II’s sympathetic actions with one 
of the three accepted models of simulated hypovolemia would 
help clarify the exact site of action and the strength of this 
blunting in hypovolemic patients. Such result is advantageous 
in determining possible interactions and side effects of future 
pharmaceutical agents.
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